Drug updates and approvals: 2019 in review

Area of Science:

• Pharmacology
• Drug Development
• Primary Care Medicine

Background:

• The U.S. Food and Drug Administration (FDA) plays a crucial role in evaluating and approving new medications.
• Primary care physicians require timely information on novel therapeutics to enhance patient treatment strategies.

Purpose of the Study:

• To summarize key drugs approved by the FDA in 2019 for primary care settings.
• To provide an overview of newly available pharmacological options for common health conditions.

Main Methods:

• Literature review of FDA drug approvals in 2019.
• Identification of drugs indicated for primary care practice.

Main Results:

• In 2019, the FDA approved risankizumab-rzaa (Skyrizi), halobetasol and tazarotene (Duobrii), dolutegravir and lamivudine (Dovato), romosozumab-aqqg (Evenity), brexanolone (Zulresso), solriamfetol (Sunosi), aclidinium and formoterol (Duaklir Pressair), and siponimod (Mayzent).

Conclusions:

• The 2019 FDA drug approvals introduced significant new therapeutic options across various medical specialties within primary care.
• These novel medications offer potential advancements in managing conditions ranging from dermatological disorders to infectious diseases and neurological conditions.